RedHill Biopharma launches trial of combination therapy for prostate cancer
Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination of opaganib and darolutamide in treating metastatic castrate-resistant prostate cancer (mCRPC). The study involves 80 male subjects …